KR102336370B1 - 당뇨병과 같은 질환의 치료를 위한 피롤리딘 gpr40 조정제 - Google Patents
당뇨병과 같은 질환의 치료를 위한 피롤리딘 gpr40 조정제 Download PDFInfo
- Publication number
- KR102336370B1 KR102336370B1 KR1020167033863A KR20167033863A KR102336370B1 KR 102336370 B1 KR102336370 B1 KR 102336370B1 KR 1020167033863 A KR1020167033863 A KR 1020167033863A KR 20167033863 A KR20167033863 A KR 20167033863A KR 102336370 B1 KR102336370 B1 KR 102336370B1
- Authority
- KR
- South Korea
- Prior art keywords
- mmol
- reaction mixture
- alkyl
- delete delete
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 C*c1ccnc2ccn[n]12 Chemical compound C*c1ccnc2ccn[n]12 0.000 description 2
- FCVRKYKSYHRZDA-UHFFFAOYSA-N Cc1ccn[n]2c1ncc2 Chemical compound Cc1ccn[n]2c1ncc2 FCVRKYKSYHRZDA-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- Y10S514/866—
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Ophthalmology & Optometry (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461989651P | 2014-05-07 | 2014-05-07 | |
| US61/989,651 | 2014-05-07 | ||
| PCT/US2015/029409 WO2015171722A1 (en) | 2014-05-07 | 2015-05-06 | Pyrrolidine gpr40 modulators for the treatment of diseases such as diabetes |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20160147049A KR20160147049A (ko) | 2016-12-21 |
| KR102336370B1 true KR102336370B1 (ko) | 2021-12-06 |
Family
ID=53181359
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020167033863A Active KR102336370B1 (ko) | 2014-05-07 | 2015-05-06 | 당뇨병과 같은 질환의 치료를 위한 피롤리딘 gpr40 조정제 |
Country Status (33)
| Country | Link |
|---|---|
| US (4) | US9873679B2 (https=) |
| EP (1) | EP3140296B1 (https=) |
| JP (1) | JP6483156B2 (https=) |
| KR (1) | KR102336370B1 (https=) |
| CN (1) | CN106458976B (https=) |
| AR (1) | AR100328A1 (https=) |
| AU (1) | AU2015256120B2 (https=) |
| BR (1) | BR112016024936A2 (https=) |
| CA (1) | CA2948161C (https=) |
| CL (1) | CL2016002809A1 (https=) |
| CY (1) | CY1120340T1 (https=) |
| DK (1) | DK3140296T3 (https=) |
| EA (1) | EA033250B1 (https=) |
| ES (1) | ES2674531T3 (https=) |
| HR (1) | HRP20180641T1 (https=) |
| HU (1) | HUE039288T2 (https=) |
| IL (1) | IL248668B (https=) |
| MA (1) | MA39427B1 (https=) |
| MX (1) | MX378160B (https=) |
| MY (1) | MY181959A (https=) |
| NZ (1) | NZ727146A (https=) |
| PE (1) | PE20161363A1 (https=) |
| PH (1) | PH12016502034B1 (https=) |
| PL (1) | PL3140296T3 (https=) |
| PT (1) | PT3140296T (https=) |
| RS (1) | RS57170B1 (https=) |
| SG (1) | SG11201609170UA (https=) |
| SI (1) | SI3140296T1 (https=) |
| SM (1) | SMT201800342T1 (https=) |
| TN (1) | TN2016000444A1 (https=) |
| TR (1) | TR201809633T4 (https=) |
| TW (1) | TWI659951B (https=) |
| WO (1) | WO2015171722A1 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2671402T3 (es) * | 2014-05-07 | 2018-06-06 | Bristol-Myers Squibb Company | Moduladores de pirrolidina GPR40 para el tratamiento de enfermedades tales como diabetes |
| EP3140296B1 (en) * | 2014-05-07 | 2018-04-11 | Bristol-Myers Squibb Company | Pyrrolidine gpr40 modulators for the treatment of diseases such as diabetes |
| JP7086942B2 (ja) | 2016-09-12 | 2022-06-20 | インテグラル ヘルス， インコーポレイテッド | Ｇｐｒ１２０モジュレーターとして有用な単環式化合物 |
| WO2018049328A1 (en) | 2016-09-12 | 2018-03-15 | Numerate, Inc. | Bicyclic compounds useful as gpr120 modulators |
| WO2018181847A1 (ja) * | 2017-03-31 | 2018-10-04 | 武田薬品工業株式会社 | 芳香環化合物 |
| BR102018007822A2 (pt) | 2017-04-20 | 2018-11-06 | Gilead Sciences, Inc. | composto, métodos para inibir pd-1, pd-l1 e/ou interação de pd-1/pd-l1 e para tratamento de câncer, composição farmacêutica, e, kit para tratamento de ou prevenção de câncer ou uma doença ou condição |
| CN110772636B (zh) * | 2017-08-21 | 2021-03-16 | 武汉大学 | Gpr31抑制剂在制备治疗心脏缺血再灌注损伤及相关疾病药物中的应用 |
| CR20200347A (es) | 2018-02-13 | 2020-09-23 | Gilead Sciences Inc | Inhibidores pd-1/pd-l1 |
| TWI712412B (zh) | 2018-04-19 | 2020-12-11 | 美商基利科學股份有限公司 | Pd‐1/pd‐l1抑制劑 |
| SG11202012425QA (en) | 2018-07-13 | 2021-01-28 | Gilead Sciences Inc | Pd-1/pd-l1 inhibitors |
| WO2020086556A1 (en) | 2018-10-24 | 2020-04-30 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
| CA3121202A1 (en) | 2018-11-30 | 2020-06-04 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
| AU2022291768A1 (en) | 2021-06-16 | 2023-11-30 | Celgene Corporation | Azetidinyl compounds comprising a carboxylic acid group for the treatment of neurodegenerative diseases |
| CN116283699B (zh) * | 2023-03-02 | 2025-02-11 | 遵义医科大学 | 一种合成氟烷基取代的吡咯烷的方法 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011044073A1 (en) | 2009-10-06 | 2011-04-14 | Bristol-Myers Squibb Company | Pyrrolidine gpr40 modulators |
| WO2014078609A1 (en) | 2012-11-16 | 2014-05-22 | Bristol-Myers Squibb Company | Pyrrolidine gpr40 modulators |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5614492A (en) | 1986-05-05 | 1997-03-25 | The General Hospital Corporation | Insulinotropic hormone GLP-1 (7-36) and uses thereof |
| US7939569B1 (en) * | 2009-12-01 | 2011-05-10 | Hoffmann-La Roche Inc. | Aniline analogs as glycogen synthase activators |
| GB2498976A (en) * | 2012-02-01 | 2013-08-07 | Prosidion Ltd | GPR119 agonists useful in the treatment of type II diabetes |
| EP2880034B1 (en) | 2012-08-01 | 2016-06-22 | Bristol-Myers Squibb Company | Amino-heteroaryl 7-hydroxy-spiropiperidine indolinyl antagonists of p2y1 receptor |
| RS55363B1 (sr) | 2012-11-16 | 2017-03-31 | Bristol Myers Squibb Co | Dihidropirazolni gpr40 modulatori |
| SG11201503562PA (en) | 2012-11-16 | 2015-06-29 | Bristol Myers Squibb Co | Dihydropyrazole gpr40 modulators |
| SG11201503556PA (en) | 2012-11-16 | 2015-06-29 | Bristol Myers Squibb Co | Dihydropyrazole gpr40 modulators |
| EP3140296B1 (en) * | 2014-05-07 | 2018-04-11 | Bristol-Myers Squibb Company | Pyrrolidine gpr40 modulators for the treatment of diseases such as diabetes |
| EP3139903B1 (en) | 2014-05-07 | 2019-07-03 | Croma-Pharma Gesellschaft m.b.H. | Aqueous ophthalmic solution and method for treating dry eye syndrome |
| WO2015171757A1 (en) | 2014-05-07 | 2015-11-12 | Bristol-Myers Squibb Company | Pyrrolidine gpr40 modulators |
-
2015
- 2015-05-06 EP EP15723095.4A patent/EP3140296B1/en active Active
- 2015-05-06 SG SG11201609170UA patent/SG11201609170UA/en unknown
- 2015-05-06 ES ES15723095.4T patent/ES2674531T3/es active Active
- 2015-05-06 MA MA39427A patent/MA39427B1/fr unknown
- 2015-05-06 US US14/705,524 patent/US9873679B2/en active Active
- 2015-05-06 PE PE2016002178A patent/PE20161363A1/es unknown
- 2015-05-06 PL PL15723095T patent/PL3140296T3/pl unknown
- 2015-05-06 DK DK15723095.4T patent/DK3140296T3/en active
- 2015-05-06 HU HUE15723095A patent/HUE039288T2/hu unknown
- 2015-05-06 SI SI201530232T patent/SI3140296T1/en unknown
- 2015-05-06 KR KR1020167033863A patent/KR102336370B1/ko active Active
- 2015-05-06 CA CA2948161A patent/CA2948161C/en active Active
- 2015-05-06 SM SM20180342T patent/SMT201800342T1/it unknown
- 2015-05-06 RS RS20180504A patent/RS57170B1/sr unknown
- 2015-05-06 TW TW104114493A patent/TWI659951B/zh active
- 2015-05-06 TN TN2016000444A patent/TN2016000444A1/en unknown
- 2015-05-06 AR ARP150101379A patent/AR100328A1/es unknown
- 2015-05-06 PT PT157230954T patent/PT3140296T/pt unknown
- 2015-05-06 EA EA201692037A patent/EA033250B1/ru not_active IP Right Cessation
- 2015-05-06 WO PCT/US2015/029409 patent/WO2015171722A1/en not_active Ceased
- 2015-05-06 MX MX2016013801A patent/MX378160B/es unknown
- 2015-05-06 MY MYPI2016704054A patent/MY181959A/en unknown
- 2015-05-06 TR TR2018/09633T patent/TR201809633T4/tr unknown
- 2015-05-06 HR HRP20180641TT patent/HRP20180641T1/hr unknown
- 2015-05-06 BR BR112016024936A patent/BR112016024936A2/pt not_active Application Discontinuation
- 2015-05-06 AU AU2015256120A patent/AU2015256120B2/en active Active
- 2015-05-06 JP JP2016566651A patent/JP6483156B2/ja active Active
- 2015-05-06 NZ NZ727146A patent/NZ727146A/en unknown
- 2015-05-06 CN CN201580022579.4A patent/CN106458976B/zh active Active
-
2016
- 2016-10-12 PH PH12016502034A patent/PH12016502034B1/en unknown
- 2016-11-01 IL IL248668A patent/IL248668B/en active IP Right Grant
- 2016-11-07 CL CL2016002809A patent/CL2016002809A1/es unknown
-
2017
- 2017-12-13 US US15/840,198 patent/US20180099949A1/en not_active Abandoned
-
2018
- 2018-05-23 CY CY20181100547T patent/CY1120340T1/el unknown
- 2018-12-06 US US16/211,848 patent/US10717725B2/en active Active
-
2020
- 2020-06-08 US US16/895,058 patent/US20200299267A1/en not_active Abandoned
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011044073A1 (en) | 2009-10-06 | 2011-04-14 | Bristol-Myers Squibb Company | Pyrrolidine gpr40 modulators |
| WO2014078609A1 (en) | 2012-11-16 | 2014-05-22 | Bristol-Myers Squibb Company | Pyrrolidine gpr40 modulators |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102336370B1 (ko) | 당뇨병과 같은 질환의 치료를 위한 피롤리딘 gpr40 조정제 | |
| JP6322202B2 (ja) | ピロリジンｇｐｒ４０修飾因子 | |
| US10301260B2 (en) | Pyrrolidine GPR40 modulators | |
| US10017497B2 (en) | Pyrrolidine GPR40 modulators for the treatment of diseases such as diabetes | |
| HK1229325B (en) | Pyrrolidine gpr40 modulators for the treatment of diseases such as diabetes | |
| HK1229325A1 (en) | Pyrrolidine gpr40 modulators for the treatment of diseases such as diabetes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20161202 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20191205 Comment text: Request for Examination of Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20210311 Patent event code: PE09021S01D |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20210907 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20211202 Patent event code: PR07011E01D |
|
| PR1002 | Payment of registration fee |
Payment date: 20211202 End annual number: 3 Start annual number: 1 |
|
| PG1601 | Publication of registration | ||
| PR1001 | Payment of annual fee |
Payment date: 20241120 Start annual number: 4 End annual number: 4 |